Skip Navigation

DRUG RECORD

 

INCRETIN-BASED DRUGS

OVERVIEW
Incretin-Based Drugs

 

The incretins are gastrointestinal polypeptide hormones that act to modulate insulin secretion from pancreatic beta cells.  These hormones include glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), and they are secreted from the upper gastrointestinal tract in response to feeding.  They act on the pancreas, causing insulin release even before blood glucose levels are elevated.  Both hormones are polypeptides that are rapidly cleared from the serum by the enzyme dipeptidyl peptidase-4 (DPP-4).  The incretin pathway provides several potential targets for therapy of type 2 diabetes, the main ones being DPP-4 inhibitors and GLP-1 analogues.  These incretin-based hypoglycemic agents are relatively new and they have not been implicated as common causes of drug induced liver injury.  These two groups of incretin-based drugs are quite different in chemical structure, pharmacology and safety profile and are discussed separately.

Drug Class:  Antidiabetic Agents


Drugs in the Subclass, Incretin-Based Drugs:


Top of page


CHEMICAL FORMULAS AND STRUCTURES
Dipeptidyl Peptidase-4 Inhibitors
DRUG CAS REGISTRY NUMBER MOLECULAR FORMULA STRUCTURE
Alogliptin 850649-62-6 C18-H21-N5-O2.C7-H6-O2 Alogliptin chemical structure
Linagliptin 668270-12-0 C25-H28-N8-O2 Linagliptin Chemical Structure
Saxagliptin 945667-22-1 C18-H25-N3-O2.H2O Saxagliptin Chemical Structure
Sitagliptin 486460-32-6 C16-H15-F6-N5-O Sitagliptin Chemical Structure

Top of page